Company Overview of Trigemina, Inc.
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.
809-B Cuesta Drive
Mountain View, CA 94040
Founded in 2006
Key Executives for Trigemina, Inc.
Founder and Chief Scientist
Compensation as of Fiscal Year 2014.
Trigemina, Inc. Key Developments
Trigemina, Inc. Presents at 9th Annual The Neurotech Investing & Partnering Conference 2014, Apr-23-2014 03:30 PM
Mar 20 14
Trigemina, Inc. Presents at 9th Annual The Neurotech Investing & Partnering Conference 2014, Apr-23-2014 03:30 PM. Venue: The Ritz Carlton, 10 Avery St., Boston, Massachusetts, United States. Speakers: Charles Yeomans, Chief Executive Officer, President and Director.
Trigemina, Inc. Announces Expansion of Phase II Study of TI-001 for Chronic Migraine
Feb 6 14
Trigemina, Inc. announced it has expanded its phase II clinical study for TI-001, intranasal oxytocin, beyond Chile to include sites in Brisbane and Adelaide, Australia. The company announced that the expansion of the Phase II study to centers in Australia demonstrates the increasing excitement and support throughout the international community in addressing one of the most urgent global needs in drug development: a safe and effective therapy for chronic migraine. This progress will place the company on track to complete enrollment of the trial in the second half of 2014. The phase II TRIG-05 study is evaluating TI-001, an investigational, nasally-delivered oxytocin therapeutic being examined to determine its efficacy, tolerability, and safety in chronic migraine patients. Secondary endpoints in this study include determining the Phase III dosage and exploring interlukin-6 (IL-6) levels as a potential biomarker for predicting efficacy. The TRIG-05 study is a placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched clinical trial expected to enroll 96 patients. If approved by the U.S. Food and Drug Administration (FDA), TI-001 could be the first non-invasive treatment approved for chronic migraine, a debilitating condition affecting more than six million Americans.
Trigemina, Inc. Initiates Phase II Clinical Trial of TI-001 for Chronic Migraine
Jun 10 13
Trigemina, Inc. announced the initiation of their Phase II clinical study investigating the use of TI-001, intranasal oxytocin, for the treatment of chronic migraine. The placebo-controlled, double-blind, randomized-withdrawal and enrollment enriched study, TRIG-05, officially began its enrollment period on May 31, 2013, and is expected to enroll 96 chronic migraine patients at trial sites located in Chile, with additional sites in Argentina expected to join in July. The first patient was enrolled in the study and treated on June 6, 2013. The primary clinical endpoint of the study is to demonstrate efficacy, tolerability and safety of TI-001, with the secondary goal of determining the best Phase III dosage and exploring interlukin-6 (IL-6) levels as a potential biomarker for predicting efficacy. If approved by the U.S. Food and Drug Administration (FDA), TI-001 could be the first non-invasive treatment approved for chronic migraine, a debilitating condition affecting more than six million Americans.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|